Senators Unveil FDA User Fee Deal Without Broad Policy Changes

Key senators late Monday released language to reauthorize industry fees to the FDA with just days left for Congress to avoid a lapse in payments that fund roughly half of the agency’s budget.

The deal, which omits previous proposals for expanded agency oversight tools, would guarantee money from industry user fees to the Food and Drug Administration for fiscal 2023 through 2027.

Lawmakers are attaching the language to a stopgap measure to keep the government funded through Dec. 16. Congress is running up on a Sept. 30 deadline to avert both a government shutdown and a lapse in user ...